← Back to search
MOLECULAR EXPRESS, INC
Doing business as MOLECULAR EXPRESS INC
RANCHO DOMINGUEZ, CA, 90220
UnclaimedClaim this profile (free)
Minority Owned
Prime contracting experience
8 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | VESIVAX TLR7 FORMULA | — | $2,999,352 | Jul 16, 2026 | Sep 1, 2024 – Aug 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | DESIGN AND ENGINEERING OF VESIVAX HIV IMMUNOGEN FORMULATIONS | — | $1,999,866 | Jun 2, 2026 | Jul 1, 2024 – Aug 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151. | — | $599,925 | Apr 10, 2025 | Sep 30, 2023 – Apr 10, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | THE CONTRACTOR SHALL TO ENGINEER NOVEL HIV GP41 ECTODOMAIN ANTIGENS (HIV GP41E-HD) FOR THE INCORPORATION INTO THE IMMUNOGENIC VESIVAX FORMULATIONS. | — | $300,000 | May 19, 2023 | Jul 1, 2022 – Aug 31, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | THE OBJECTIVE OF THIS CONTRACT IS TO IDENTIFY A POTENTIAL HIV ANTIGEN-CONJUGATED VACCINE FORMULATION BY EXPLORING CO-DELIVERY OF HIV ANTIGENS AND ADJUVANT MOLECULES. | — | $299,961 | Jan 6, 2023 | Jun 1, 2020 – May 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN. | — | $299,993 | Sep 22, 2022 | Jun 1, 2020 – Jul 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | THE CONTRACTOR SHALL TO EVALUATE THE DIFFERENT CO-DELIVERY METHODS OF A MODEL HIV ANTIGEN USING THE VESIVAX LIPOSOMAL PLATFORM. | — | $2,294,565 | Jun 23, 2022 | Jul 1, 2021 – Jul 31, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | DEVELOPMENT OF A VESIVAS IMMUNOSIMILAR FORMULATION | — | $569,807 | Feb 25, 2022 | Aug 1, 2021 – Jul 31, 2023 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.